All News

All the participants were in the Beating Lung Cancer in Ohio study, which started before the COVID-19 pandemic.

Niraparib is associated with increased progression-free survival, regardless of the presence or absence of BRCA gene mutations.

Pharmacists can play a critical role in this therapy, panelists in a recent Pharmacy Times® Peer Exchange say.

If approved, Dipilumab will be the first biologic medicine available in the United States to treat uncontrolled moderate-to-severe AD for patients aged 6 months to 5 years.

FlorastorKids is a daily probiotic supplement for children’s digestive and immune support.

Ozempic is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Though target medication safety best practices was created with hospitals in mind, community pharmacies can also benefit from these practices.

NVX-CoV2373 (Novavax) was found to provide 100% protection against moderate and severe disease and 90.4% efficacy overall in a phase 3 trial last year.

Sachin Nagrani, MD, the medical director of Heal, discusses Pfizer’s research assessing an Omicron-specific vaccine for adults aged 18 to 55 years.

Adversity has disproportionately hurt certain populations, including essential workers and women, the results of a new analysis show.

Prior studies indicate that CPAP treatment can significantly decrease sleepiness and depression while also protecting against high blood pressure.

One out of every 4 pharmacists in Georgia said emergency contraception was not available at the store and ended the call.

The claim is based on requested exemption from administering immunizations because of "needle phobia."

Rachel Rubin, MD, an assistant clinical professor in urology at Georgetown and a urologic surgeon, discusses hypoactive sexual desire disorder and the current treatments available for this medical condition.

Ronald T. Piervincenzi, CEO of US Pharmacopeia, discusses how building resilience in the medicine supply chain will help bolster preparedness for what may arise during the COVID-19 pandemic and beyond.

This Valentine’s Day, pharmacists can remind patients that they may not need to feel guilty when they indulge in a small piece of chocolate.

Envive reduces bloating, diarrhea, constipation, gas, and discomfort.

Tresiba is indicated to improve glycemic control in patients with diabetes.

Bebtelovimab gets Emergency Use Authorization to treat mild-to-moderate COVID-19 in adults and pediatric patients who are at high risk for progression to severe COVID-19.

Ronald T. Piervincenzi, CEO of US Pharmacopeia, discusses contributing factors leading to health care professionals experience of an erosion of trust in the medicine supply chain.

Tiago Reis Marques, MD, PhD, CEO of Pasithea Therapeutics, discusses the future of ketamine and psychedelic medicines in the treatment of mental health and brain disorders.

In the fourth episode of Coffee With Suzy, we listened back to some of the best moments from the series so far.

The drug's novel molecular structure may result in fewer toxic adverse effects.

New analysis shows the substitution would cut costs by $600 million in the United States annually.

American Heart Month is another example of the essential and valuable position that pharmacists hold in improving health care outcomes and optimizing patient-centered care.

Ronald T. Piervincenzi, CEO of US Pharmacopeia, discusses how drug shortages are related to medicine quality issues.

Study shows that 98% of cases of multi-system inflammatory syndrome in children (MIS-C) were unvaccinated, suggesting that vaccination reduces the chance of a child who had COVID-19 later developing MIS-C.

Genentech has released new 2-year data for individuals with diabetic macular edema and wet age-related macular degeneration.

The lingering effects of the COVID-19 pandemic, including supply concerns and staffing shortages, have made technological solutions become more crucial.

Ronald T. Piervincenzi, CEO of US Pharmacopeia (USP), discusses recent survey data demonstrating 90% of physicians had experienced an erosion of trust in the US supply chain’s ability to deliver safe, quality medicines.